Literature DB >> 9228082

Differential regulation of phosphoinositide 3-kinase adapter subunit variants by insulin in human skeletal muscle.

P R Shepherd1, B T Navé, J Rincon, L A Nolte, A P Bevan, K Siddle, J R Zierath, H Wallberg-Henriksson.   

Abstract

The role of phosphoinositide 3-kinase (PI 3-kinase) in insulin signaling was evaluated in human skeletal muscle. Insulin stimulated both antiphosphotyrosine-precipitable PI 3-kinase activity and 3-O-methylglucose transport in isolated skeletal muscle (both approximately 2-3-fold). Insulin stimulation of 3-O-methylglucose transport was inhibited by the PI 3-kinase inhibitor LY294002 (IC50 = 2.5 microM). The PI 3-kinase adapter subunits were purified from muscle lysates using phosphopeptide beads based on the Tyr-751 region of the platelet-derived growth factor receptor. Immunoblotting of the material adsorbed onto the phosphopeptide beads revealed the presence of p85alpha, p85beta, p55(PIK)/p55gamma, and p50 adapter subunit isoforms. In addition, p85alpha-NSH2 antibodies recognized four adapter subunit variants of 54, 53, 48, and 46 kDa, the latter corresponding to the p50 splice variant. Serial immunoprecipitations demonstrated that these four proteins were associated with a large proportion of the total PI 3-kinase activity immunoprecipitated by p85alpha-NSH2 domain antibodies. Antibodies to p85beta, p55(PIK)/p55gamma, and the p50 adapter subunit also immunoprecipitated PI 3-kinase activity from human muscle lysates. A large proportion of the total cellular pool of the 53-kDa variant, p50, and p55(PIK) was present in antiphosphotyrosine immunoprecipitates from unstimulated muscle, whereas these immunoprecipitates contained only a very small proportion of the cellular pool of p85alpha, p85beta, and the 48-kDa variant. Insulin greatly increased the levels of the 48-kDa variant in antiphosphotyrosine immunoprecipitates and caused smaller -fold increases in the levels of p85alpha, p85beta, and the 53-kDa variant. The levels of p50 and p55(PIK) were not significantly changed. These properties indicate mechanisms by which specificity is achieved in the PI 3-kinase signaling system.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9228082     DOI: 10.1074/jbc.272.30.19000

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Positive and negative regulation of phosphoinositide 3-kinase-dependent signaling pathways by three different gene products of the p85alpha regulatory subunit.

Authors:  K Ueki; P Algenstaedt; F Mauvais-Jarvis; C R Kahn
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

Review 2.  Insulin signaling defects in type 2 diabetes.

Authors:  Ying Leng; Håkan K R Karlsson; Juleen R Zierath
Journal:  Rev Endocr Metab Disord       Date:  2004-05       Impact factor: 6.514

Review 3.  Insulin action in skeletal muscle from patients with NIDDM.

Authors:  J R Zierath; A Krook; H Wallberg-Henriksson
Journal:  Mol Cell Biochem       Date:  1998-05       Impact factor: 3.396

4.  Expression of the splice variants of the p85alpha regulatory subunit of phosphoinositide 3-kinase in muscle and adipose tissue of healthy subjects and type 2 diabetic patients.

Authors:  E Lefai; M Roques; N Vega; M Laville; H Vidal
Journal:  Biochem J       Date:  2001-11-15       Impact factor: 3.857

5.  Molecular mechanisms of contraction-regulated cardiac glucose transport.

Authors:  M Till; D M Ouwens; A Kessler; J Eckel
Journal:  Biochem J       Date:  2000-03-15       Impact factor: 3.857

6.  Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling.

Authors:  Claire Chaussade; Gordon W Rewcastle; Jackie D Kendall; William A Denny; Kitty Cho; Line M Grønning; Mei Ling Chong; Sasha H Anagnostou; Shaun P Jackson; Nathalie Daniele; Peter R Shepherd
Journal:  Biochem J       Date:  2007-06-15       Impact factor: 3.857

Review 7.  Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling.

Authors:  P R Shepherd; D J Withers; K Siddle
Journal:  Biochem J       Date:  1998-08-01       Impact factor: 3.857

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.